Mary K. Brainerd, a director at medical technology company Stryker Corp., purchased 131 shares of the company indirectly through her husband's revocable trust, according to regulatory filings. The transactions, completed between June 2019 and November 2022, totaled $26,736 at prices ranging from $185.65 to $225.195 per share.
The purchases were made as part of Brainerd's holdings, which are primarily managed through the revocable trust. Separately, 7,790 shares were disposed of in an unreported transaction, and 11 shares initially held in Brainerd's IRA were transferred to the revocable trust on September 1, 2026.
Stryker reported adjusted earnings per share of $3.69 for the second quarter of fiscal year 2026, exceeding Wall Street expectations of $3.49. Revenue reached $6.6 billion, surpassing analyst estimates of $6.58 billion. Organic revenue growth for the quarter was 9%, while year-over-year EPS increased by 18%, outpacing consensus by 6 percentage points.
The company cited a sales recovery following a cybersecurity incident early in the year and ongoing supply chain disruptions in the first half of fiscal 2026 as contributing factors to its performance. Stryker also raised the lower bound of its fiscal 2026 organic growth guidance by 30 basis points and adjusted its full-year EPS guidance upward by $0.05.
Analysts at Wolfe Research increased Stryker's price target from $350 to $375, maintaining an Outperform rating. Citizens, however, trimmed its target from $440 to $400 while keeping a Market Outperform rating. Stryker's market capitalization stands at $119.95 billion, with shares trading at $312.19.
